Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel

Urology

Volumn 70, Issue 2, 2007, Pages 396-401

  Zhang, Zhengwang ^a   Stanfield, Jennifer ^a   Frenkel, Eugene ^a   Kabbani, Wareef ^a   Hsieh, Jer Tsong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DEPSIPEPTIDE; DOCETAXEL; FR 901228; HISTONE DEACETYLASE INHIBITOR; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR REGRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEPSIPEPTIDES; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 34548438593     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.052     Document Type: Article

References (24)

1. Kopelovich L., Crowell J.A., and Fay J.R. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 95 (2003) 1747-1757
2. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
3. Ueda H., Nakajima H., Hori Y., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968.I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47 (1994) 301-310
4. Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103 (2004) 4636-4643
5. Sato N., Ohta T., Kitagawa H., et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24 (2004) 679-685
6. Tsurutani J., Soda H., Oka M., et al. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 104 (2003) 238-242
7. Burgess A., Ruefli A., Beamish H., et al. Histone deacetylase inhibitors specifically kill nonproliferating tumor cells. Oncogene 23 (2004) 6693-6701
8. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol 22 (2004) 4632-4642
9. Chen J.G., and Horwitz S.B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 62 (2002) 1935-1938
10. Huang J., Nasr M., Kim Y., et al. Genistein inhibits protein histidine kinase. J Biol Chem 267 (1992) 15511-15515
11. Wu H.C., Hsieh J.T., Gleave M.E., et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57 (1994) 406-412
12. Tseng C.P., Ely B.D., Li Y., et al. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 139 (1998) 3542-3553
13. Kanamaru H., and Yoshida O. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay. Urol Res 17 (1989) 259-264
14. Zhao L., Wientjes M.G., and Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10 (2004) 7994-8004
15. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66 (1975) 188-193
16. Glantz S.A. Primer of Biostatistics. 3rd ed. (1992), McGraw-Hill, New York 278-319
17. Piekarz R., and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm 10 (2004) 2289-2298
18. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 40 (2005) 1-13
19. Zhang Z., Karam J., Frenkel E., et al. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 24 (2006) 152-160
20. Furumai R., Matsuyama A., Kobashi N., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62 (2002) 4916-4921
21. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
22. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
23. Petrylak D.P. Future directions in the treatment of androgen-independent prostate cancer. Urology 65 (2005) 8-12
24. Marks P.A., and Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4 (2005) 549-551